This study reveals that the remodeling of GAM phenotypes results from the alteration of tumoral cholesterol homeostasis via IDH mutation‐induced PERK activation, highlighting PERK as a promising therapeutic target for the treatment of glioma. The gene discussed is IDH1; the disease is glioma.